Head and Neck Pathology

, Volume 4, Issue 4, pp 295–299

Collision Tumor of Primary Laryngeal Mucosal Melanoma and Invasive Squamous Cell Carcinoma with IL-17A and CD70 Gene Over-Expression

  • Sasis Sirikanjanapong
  • Biana Lanson
  • Milan Amin
  • Frank Martiniuk
  • Hideko Kamino
  • Beverly Y. Wang
Case Report


The most common primary malignancy of the larynx is the squamous cell carcinoma (SCC). The primary malignant melanoma is quite rare in this location. Less than 60 cases of laryngeal melanomas have been reported to date. To our knowledge, collision primary malignant melanoma and invasive squamous cell carcinoma in the vocal cords has not been reported. We report a 53-year-old male patient who was diagnosed with a collision tumor of laryngeal melanoma and invasive SCC. Multiple Th17 pathway related genes including CTLA-4, IL-17A-F, PLZF, FoxP3, RorγT, CD27, and CD70 were analyzed by reverse transcriptase-polymerase chain reaction (Rt–PCR) in this case. Both IL-17A and CD70 genes were detected in this case of collision tumor. The results may define useful biomarkers for early diagnosis of mucosal melanoma and open an immunotherapeutic field for clinical management with the potential benefit from the immunomodulators that enhance both genes.


Collision tumor Laryngeal mucosal melanoma Squamous cell carcinoma IL-17A and CD70 genes 


  1. 1.
    Marur S, Forastiere AA. Head and neck cancer: changing epidemiology, diagnosis, and treatment. Mayo Clin Proc. 2008;83:489–501.CrossRefPubMedGoogle Scholar
  2. 2.
    Barnes L. Surgical pathology of the head and neck, 3rd edn. Informa Healthcare. New York; 2008. pp. 137–160.Google Scholar
  3. 3.
    Chang AE, Karnell LH, Menck HR. The National Cancer Data Base Report on cutaneous and non cutaneous melanoma. A summary of 84,836 cases from the past decade. Cancer. 1998;83:1664–78.CrossRefPubMedGoogle Scholar
  4. 4.
    Wagner M, Morris CG, Werning JW, et al. Mucosal melanoma of the head and neck. Am J Clin Oncol. 2008;31:43–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Wenig BM. Laryngeal mucosal malignant melanoma. A clinicopathologic, immunohistochemical, and ultrastructural study in four patients and a review of the article. Cancer. 1995;75:1568–77.CrossRefPubMedGoogle Scholar
  6. 6.
    Wang W, Edington HD, Rao UN, et al. Effects of high-dose IGNα2b on regional lymph node metastases of human melanoma: modulation of STAT5, Foxp3, and IL-17. Clin Cancer Res. 2008;14:8314–20.CrossRefPubMedGoogle Scholar
  7. 7.
    Patrick RJ, Fenske NA, Messina JL. Primary mucosal melanoma. J Am Acad Dermatol. 2007;56:828–34.CrossRefPubMedGoogle Scholar
  8. 8.
    Shah JP, Huvos AG, Strong EW. Mucosal melanomas of the head and neck. Am J Surg. 1977;134:531–5.CrossRefPubMedGoogle Scholar
  9. 9.
    Reuter VE, Woodruff JM. Melanoma of the larynx. Laryngoscope. 1986;94:389–93.Google Scholar
  10. 10.
    Terada T, Saeki N, Toh K, et al. Primary malignant melanoma of the larynx: a case report and review literature. Auris Nasus Larynx. 2007;34:105–10.CrossRefPubMedGoogle Scholar
  11. 11.
    Kim H, Park CI. Primary malignant laryngeal melanoma: report of a case with a review of literature. Yonsei Med J. 1982;23:118–22.PubMedGoogle Scholar
  12. 12.
    Tomidokoro Y, Hayashi R, Yamasaki M, et al. Simultaneous squamous cell carcinoma with leimomyosarcoma of the larynx. Auris Nasus Larynx. 2009;36:239–43.CrossRefPubMedGoogle Scholar
  13. 13.
    Medina-Banegas A, Osete-Albaladejo JM, Capitan-Guarnizo A, et al. Double tumor of the larynx: a case report. Eur Arch Otolaryngol. 2003;260:341–3.CrossRefGoogle Scholar
  14. 14.
    Allen AC, Spitz S. Malignant melanoma: a clinicopathological analysis of the criteria for diagnosis and prognosis. Cancer. 1953;6:1–45.CrossRefPubMedGoogle Scholar
  15. 15.
    Moore ES, Martin H. Melanoma of the upper respiratory tract and oral cavity. Cancer. 1955;8:1167–76.CrossRefPubMedGoogle Scholar
  16. 16.
    Amin HM, Petruzzelli GJ, Husain AN, et al. Primary malignant melanoma of the larynx. Arch Pathol Lab Med. 2001;125:271–3.PubMedGoogle Scholar
  17. 17.
    Morris LG, Wen YH, Nonaka D, et al. Melanocytic marker in immunohistochemical evaluation of primary mucosal melanoma of the head and neck. Head Neck. 2008;30:771–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Muranski P, Boni A, Antony PA, et al. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. 2008;112:362–73.CrossRefPubMedGoogle Scholar
  19. 19.
    Yamaguchi Y, Fujio K, Shoda H, et al. IL-17B and IL-17C are associated with TNF-α production and contribute to the exacerbation of inflammatory arthritis. J Immunol. 2007;179:7128–36.PubMedGoogle Scholar
  20. 20.
    von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med. 2009;7:35.CrossRefGoogle Scholar
  21. 21.
    Cormary C, Gonzalez R, Faye JC, et al. Induction of T-cell antitumor immunity and protection against tumor growth by secretion of soluble human CD70 molecules. Cancer Gene Ther. 2004;11:497–507.CrossRefPubMedGoogle Scholar
  22. 22.
    Garley M, Jablonska E, Grabowska SZ, et al. IL-17 family cytokines in neutrophils of patients with oral epithelial squamous cell carcinoma. Neoplasma. 2009;56:96–100.CrossRefPubMedGoogle Scholar
  23. 23.
    Langowski JL, Zhang X, Wu L, et al. IL-23 promotes tumour incidence and growth. Nature. 2006;442:461–5.CrossRefPubMedGoogle Scholar
  24. 24.
    Overwijk WW, de Visser KE, Tirion FH, et al. Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant. J Immunol. 2006;176:5213–22.PubMedGoogle Scholar
  25. 25.
    Numasaki M, Watanabe M, Suzuki T, et al. IL-17 enhances the net angiogenic activity and in vivo growth of human non-small cell lung cancer in SCID mice through promoting CXCR-2-dependent angiogenesis. J Immunol. 2005;175:6177–89.PubMedGoogle Scholar
  26. 26.
    Kryczek I, Wei S, Zou L, et al. Cutting edge: Th17 and regulatory T cell dynamics and the regulation by IL-2 in the tumor microenvironment. J Immunol. 2007;178:6730–3.PubMedGoogle Scholar
  27. 27.
    Wang L, Yi T, Kortylewski M, et al. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457–64.CrossRefPubMedGoogle Scholar
  28. 28.
    Cormary C, Hiver E, Mariamé B, et al. Coexpression of CD40L and CD70 by semiallogenic tumor cells induces anti-tumor immunity. Cancer Gene Ther. 2005;2:963–72.CrossRefGoogle Scholar
  29. 29.
    Couderc B, Zitvogel L, Douin-Echinard V, et al. Enhancement of antitumor immunity by expression of CD70 (CD27 ligand) or CD154 (CD40 ligand) costimulatory molecules in tumor cells. Cancer Gene Ther. 1998;5:163–75.PubMedGoogle Scholar
  30. 30.
    Snow GB, VanDerEsch EP, Van Sloanten EA. Mucosal melanomas of the head and neck. Head Neck Surg. 1978;1:24–30.CrossRefPubMedGoogle Scholar

Copyright information

© Humana 2010

Authors and Affiliations

  • Sasis Sirikanjanapong
    • 1
  • Biana Lanson
    • 2
  • Milan Amin
    • 2
  • Frank Martiniuk
    • 3
  • Hideko Kamino
    • 4
  • Beverly Y. Wang
    • 1
    • 2
  1. 1.Department of PathologyNew York University School of MedicineNew YorkUSA
  2. 2.Department of OtolaryngologyNew York University School of MedicineNew YorkUSA
  3. 3.Department of MedicineNew York University School of MedicineNew YorkUSA
  4. 4.Department of DermatopathologyNew York University School of MedicineNew YorkUSA

Personalised recommendations